Retatrutide and TRIUMPH-4

Retatrutide reduced knee-pain scores more than placebo in TRIUMPH-4, a trial in adults with knee osteoarthritis and obesity or overweight. The findings concern reported pain, function and weight. They do not establish that retatrutide rebuilds cartilage. 2 3

What is new at ACR 2026?

Lilly announced the ACR presentation on November 5, with the TRIUMPH-4 session scheduled for November 8 at 11:15 a.m. Eastern Time. The headline results were first released on December 11, 2025. This is conference coverage of an existing trial, not a newly completed study or an approval announcement. 1 4

Who took part in TRIUMPH-4?

ClinicalTrials.gov records 445 participants in a randomized, double-blind Phase 3 study. Eligibility included a body mass index of at least 27, persistent knee pain and moderate radiographic osteoarthritis. People with diabetes or a different joint disease were excluded. Pain and body-weight change were the two primary outcomes at week 68. 3

That population matters when interpreting the result. A study enrolling people with painful knee osteoarthritis and excess weight does not answer the same question as a trial in athletes with an acute injury, people without excess weight or patients with inflammatory arthritis. 3

How did the results compare with placebo?

The conference abstract reports the following mean changes at 68 weeks. Its efficacy figure uses an efficacy estimand. Negative pain-score values mean improvement; the placebo group also improved substantially. These are group averages from trial regimens, not instructions for personal use. 2

2

What does the large percentage headline mean?

The frequently quoted 75.8% pain reduction describes change from the retatrutide group’s own baseline. It is not a 75.8% advantage over placebo. Lilly also identifies the percentage changes in WOMAC pain and physical-function scores as post-hoc calculations rather than prespecified percentage endpoints. 4

Pain scores, physical function and joint structure are separate outcomes. The registered primary endpoints do not measure cartilage regeneration. The trial also does not, by itself, separate how much pain improvement comes from weight change versus other biological effects. 3

What about adverse effects and remaining uncertainty?

The abstract describes gastrointestinal events as the most common adverse effects, generally mild or moderate. In Lilly’s earlier report, adverse-event discontinuation occurred in 12.2% and 18.2% of the two retatrutide groups, versus 4.0% with placebo. These findings qualify the efficacy results. 2 4

An efficacy estimand evaluates treatment effects under specified assumptions; it is not a forecast for every person starting therapy. The earlier sponsor report also presents a treatment-regimen estimand, which addresses discontinuation differently. Comparing results requires keeping those analyses separate. 4

Retatrutide remains investigational in Lilly’s current announcement. This article checks the public abstract, registry and sponsor reports; it does not claim review of patient-level data or the conference presentation itself. Trial findings cannot establish equivalence for a separately supplied research material. 1

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.